CMS Entry id: 2709 | Channel: Blog landing page | Template: blog/index

Login
Facebook YouTube Twitter Linkedin
Facebook YouTube Twitter Linkedin

Blog

New Commercial Partnership and Further Scientific Validation for NeuroVocalix

Cambridge Cognition is pleased to announce the second commercial partnership with a leading pharmaceutical company, for its NeuroVocalixTM platform. NeuroVocalixTM is a unique voice biomarker technology and the product was launched last year and recently presented ground-breaking demonstrable evidence of the potential at a major global Alzheimer’s conference.  

NeuroVocalix platform ready for clinical trials

NeuroVocalix enables novel voice-based cognitive assessments to be delivered directly to patients through mobile and tele-health platforms, helping to improve outcomes in clinical trials, aid clinical decision-making and play an important role in the management of long-term conditions such as chronic pain.